創勝集團 - 全整合型國際化生物制藥公司

創勝集團, 生物藥, 抗體, 藥物研發

創勝集團 - 全整合型國際化生物制藥公司

加入我們 聯繫我們
學術論文及會議壁報

TranStar102-Cohort C 研究:Osemitamab (TST001)聯合卡培他濱和奧沙利鉑 (CAPOX)一線治療 CLDN18.2 陽性晚期胃/胃食管結合部腺癌的更新療效數據

23 Oct, 2023

Author:

Lin Shen1, Dan Liu1, Ning Li2, Weijian Guo3, Tianshu Liu4, Lijuan Zhang5, Xuelian, Zhu5, Chuan Qi5, Xu Li5, Xueming Qian5, Caroline Germa5.
1. Peking University Cancer Hospital; 2. Henan Cancer Hospital; 3. Fudan University Cancer Center; 4. Fudan University Affiliated Zhongshan Hospital; 5. Suzhou Transcenta Therapeutics Co, Ltd.

Background:

• Phase 3 studies (SPOTLIGHT and GLOW) showed that combining anti-CLDN18.2 antibody with chemotherapy significantly improved PFS and OS as first-line treatment for G/GEJ (gastric/gastroesophageal junction) cancer with CLDN18.2 expression above 75%, 2/3+ per Astellas CDx (~38% of all G/GEJ cancer patients).
• TST001 (osemitamab) is a potential best-in-class antibody with improved CLDN18.2 affinity and enhanced ADCC effect, leading to anti-tumor activity in low to medium CLDN18.2 expression gastric cancer animal models.
• The preliminary efficacy of TST001 in combination with CAPOX in the patients with advanced G/GEJ cancer was reported previously in ASCO and ESMO-GI. Here we present the updated analysis in the patients from dose expansion phase who had received TST001 at 6mg/kg Q3W and CAPOX.

Conclusions:

• Phase 3 studies (SPOTLIGHT and GLOW) showed that combining anti-CLDN18.2 antibody with chemotherapy significantly improved PFS and OS as first-line treatment for G/GEJ (gastric/gastroesophageal junction) cancer with CLDN18.2 expression above 75%, 2/3+ per Astellas CDx (~38% of all G/GEJ cancer patients).
• TST001 (osemitamab) is a potential best-in-class antibody with improved CLDN18.2 affinity and enhanced ADCC effect, leading to anti-tumor activity in low to medium CLDN18.2 expression gastric cancer animal models.
• The preliminary efficacy of TST001 in combination with CAPOX in the patients with advanced G/GEJ cancer was reported previously in ASCO and ESMO-GI. Here we present the updated analysis in the patients from dose expansion phase who had received TST001 at 6mg/kg Q3W and CAPOX.